The US Supreme Court case concerning Myriad Genetics' patent claims on BRCA 1 and BRCA 2 is an important battle in a fight for freedom — genomic freedom — and those claims just represent "the tip of the iceberg," Chris Mason argues in the Huffington Post.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.